Gilead (GILD)

Executive Summary

Gilead Sciences is a global biopharmaceutical leader with a strong legacy in virology, particularly HIV and hepatitis, and a growing presence in oncology and inflammation. The company's robust pipeline includes lenacapavir, a novel capsid inhibitor for HIV treatment and prevention, which could significantly expand its market in pre-exposure prophylaxis (PrEP). In oncology, Gilead's Trodelvy has shown promise in multiple indications, including breast and lung cancers, and the company is advancing its cell therapy and antibody-drug conjugate platforms. Despite recent setbacks in some pipeline assets, Gilead's financial stability, commercial portfolio of over 20 products, and strategic acquisitions position it well for sustained growth. The company continues to generate substantial revenue from its HIV franchise, providing a solid base for investment in emerging therapies. With upcoming regulatory decisions and pivotal trial readouts, Gilead is poised to address key unmet medical needs while navigating competitive pressures in virology and oncology.

Upcoming Catalysts (preview)

• Q2 2026FDA decision on lenacapavir for HIV PrEP85% success
• Q3 2026Phase 3 readout for Trodelvy in first-line metastatic non-small cell lung cancer (EVOKE-01)70% success
• Q4 2026Phase 2 data for Gilead's bispecific antibody in inflammatory bowel disease60% success